Ikarian Capital’s vTv Therapeutics VTVT Stock Holding History

Ikarian Capital’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18,575	Closed	-$536K	–	205
2022 Q1	$536K	Buy	18,575 +1,075	+6%	+$32.2K	0.07%	134
2021 Q4	$697K	Buy	+17,500	New	+$940K	0.1%	116

Other funds holding VTVT

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SQA

Simon Quick Advisors Morristown, New Jersey $2.19B AUM 17.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Ikarian Capital's VTVT Position: Q2 2022 in Review

Ikarian Capital sold out of vTv Therapeutics (VTVT) in Q2 2022, closing a stake of 18,575 shares — an estimated $536K sold.

Ikarian Capital first reported a position in VTVT in Q4 2021 and held it in 2 quarters. The position peaked at $697K in Q4 2021. 23 funds tracked by Wall St. Rank hold VTVT as of Q2 2022.

Ikarian Capital reported no remaining vTv Therapeutics position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 18,575 vTv Therapeutics shares in Q2 2022, an estimated $536K.
Ikarian Capital first reported a position in vTv Therapeutics in Q4 2021 and held it in 2 quarters.
Ikarian Capital's vTv Therapeutics position peaked at $697K in Q4 2021.
23 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.